Prime Medicine, Inc. Capital Expenditures Incurred but Not yet Paid
Prime Medicine, Inc. (PRME) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $0.00.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $114.00K, a 89.07% decline year-over-year.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$148.00K.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $114.00K, a 90.12% decline from fiscal 2024.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $1.15M, a 100.70% increase from fiscal 2023.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $575.00K, a 40.66% decline from fiscal 2022.
- Prime Medicine, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $969.00K, a 28.51% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $114.00K derived: sum of 3 quarters · filed 2026-08-06 | -$34.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $114.00K derived: sum of 2 quarters · filed 2026-05-07 | -$34.00K derived: sum of 3 quarters · filed 2026-05-07 | -$871.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$34.00K derived: sum of 2 quarters · filed 2026-03-03 | -$871.00K derived: sum of 3 quarters · filed 2026-08-06 | $114.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | -$148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$985.00K derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-07 | $1.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$837.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $148.00K 10-Q · filed 2026-08-06 | $1.19M derived: sum of 3 quarters · filed 2026-08-06 | $947.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $985.00K 10-Q · filed 2026-05-07 | $2.03M derived: sum of 2 quarters · filed 2026-05-07 | $1.78M derived: sum of 3 quarters · filed 2026-05-07 | $1.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $799.00K derived: sum of 2 quarters · filed 2026-03-03 | $321.00K derived: sum of 3 quarters · filed 2026-03-03 | $1.15M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$244.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$722.00K derived: sum of 2 quarters · filed 2025-11-07 | $111.00K 10-Q · filed 2025-11-07 | $173.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$478.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $355.00K 10-Q · filed 2025-08-07 | $417.00K derived: sum of 3 quarters · filed 2025-08-07 | $218.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $833.00K 10-Q · filed 2025-05-08 | $895.00K derived: sum of 2 quarters · filed 2025-05-08 | $696.00K derived: sum of 3 quarters · filed 2025-05-08 | -$1.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$137.00K derived: sum of 2 quarters · filed 2025-02-28 | -$2.03M derived: sum of 3 quarters · filed 2025-02-28 | $575.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | -$199.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.09M derived: sum of 2 quarters · filed 2024-11-12 | $513.00K 10-Q · filed 2024-11-12 | $612.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $712.00K 10-Q · filed 2024-08-08 | $811.00K derived: sum of 3 quarters · filed 2024-08-08 | -$902.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.60M 10-Q · filed 2024-05-10 | $2.70M derived: sum of 2 quarters · filed 2024-05-10 | $989.00K derived: sum of 3 quarters · filed 2024-05-10 | $2.43M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$1.61M derived: sum of 2 quarters · filed 2024-03-01 | -$175.00K derived: sum of 3 quarters · filed 2024-03-01 | $969.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$274.00K derived: sum of 2 quarters · filed 2023-11-03 | $870.00K 10-Q · filed 2023-11-03 | $1.62M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.58M 10-Q · filed 2023-08-07 | $3.34M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $1.14M 10-Q · filed 2023-05-11 | $1.90M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $754.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $754.00K 10-K · filed 2023-03-09 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |